San Diego—A new study suggests that metallic Resonance ureteral stents are a good option for management of malignant ureteral obstruction because they promote strong long-term outcomes.
The stents offer "excellent treatment outcomes and improved cost effectiveness," said study co-author Philippe E Spiess, MD, MS, of Moffitt Cancer Center and the University of South Florida, Tampa.
According to Dr. Spiess, metallic ureteral stents offer an alternative to traditional polymer stents and require annual exchanges instead of once every 3-4 months.
"Over recent years, several retrospective studies have been performed to validate their efficacy and longevity in the setting of malignant ureteral obstructions of various genitourinary and non-genitourinary etiologies," he said. "However, there is limited data on their long-term viability and outcomes."
Only one kind of metallic ureteral stent—the Resonance—is available for use in the U.S., said study co-author Timothy Juwono, MD, of the University of South Florida Morsani College of Medicine.
For the new single-center study, which was presented at the 2017 American College of Surgeons Clinical Congress in San Diego, the authors tracked 148 metallic Resonance ureteral stents that were placed in 80 cases of malignant ureteral obstruction from 2009-2016.
"Our patients were managed with Resonance metallic ureteral stent for a range of between 24-83 months with a median of five stent exchanges during the study duration. The median stent life was 10 months, which is 6-7 months longer than the traditional polymer stent," Dr. Juwono said.